

Cognitive performance and psychiatric symptoms in de novo, untreated Parkinson's disease: results from the PPMI study

Daniel Weintraub¹, Tanya Simuni², Christopher Coffey³, Eric Foster³, Lama Chahine¹, Irene Litvan⁴, Matt Troyer⁵, Andrew Siderowf⁶, Keith Hawkins⁷ for the PPMI Cognitive Behavioral Working Group* and PPMI Investigators**

¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; ²Northwestern University, Chicago, IL; ³University of Iowa, Iowa City, IA; ⁴University of California, San Diego, San Diego, CA; ⁵Merck, Whitehouse Station , NJ; ⁶Avid Radiopharmaceuticals, Philadelphia, PA; ⁷Yale School of Medicine, New Haven, CT

Background

- Preliminary studies suggest that cognitive impairment (CI) and neuropsychiatric symptoms (NPS) are common in newly diagnosed Parkinson’s disease (PD) patients.
- Objective: To determine the frequency and correlates of CI and NPS in a large cohort of early, untreated PD patients and comparable group of healthy controls (HCs).

Study Design

- PPMI is an international, multi-site, case-control study conducted at 24 academic centers.
- Participants are recently diagnosed, untreated PD patients or HCs. HCs with cognitive impairment (Montreal Cognitive Assessment (MoCA) score <26 were excluded).
- Detailed cognitive and NPS battery is performed at baseline.

Linear Regression Model for MoCA Score in PD Patients

Variable	Parameter Estimate	Standard Error	Pr > F
Intercept	28.22970	0.63592	<.0001
Age	-0.45075	0.13214	0.0007
Gender	-0.45387	0.22224	0.0418
Education	0.78446	0.27501	0.0046
UPDRS Part III Score	-0.02646	0.01216	0.0301

Model used Backward Selection at 0.05 level of significance

Characteristics

Variable (N [%] or mean)	PD Subjects (N =416)	Healthy Controls (N =191)	p-value (PD vs. HC)
Demographics			
Male	272 (65%)	121 (63%)	0.65
Age (Mean)	61.7	60.5	0.17
Education <13 Years	75 (18%)	28 (15%)	0.36
Education 13-23 Years	338 (81%)	163 (85%)	
Education >23 Years	3 (1%)	0 (0%)	
Not Hispanic/Latino	407 (98%)	188 (98%)	0.76
White	384 (92%)	177 (93%)	1.00
Black/African-American	6 (1%)	9 (5%)	
Asian	8 (2%)	1 (1%)	
UPDRS Mean Score & Sub Scores			
MDS-UPDRS Total Score	32.3	4.7	<0.01
MDS-UPDRS Part III (Motor)	20.9	1.2	<0.01
Hoehn & Yahr Stage			
Stage 0	0 (0%)	188 (98%)	<0.01
Stage 1	181 (44%)	2 (1%)	
Stage 2	232 (56%)	0 (0%)	
Stage 3-5	2 (0%)	0 (0%)	
Duration of Disease			
Mean (months)	6.6	NA	NA
TD/PIGD Classification			
TD	296 (71%)	NA	NA
PIGD	73 (18%)	NA	
Indeterminate	45 (11%)	NA	

Psychiatric / Non-Motor Symptoms

Variable (N [%] or mean)	PD Subjects (N = 416)	Healthy Controls (N = 191)	p-value (PD vs. HC)
GDS-15 Score			<0.01
Mean	2.3	1.3	
GDS Score			0.01
Depressed (≥5)	58 (14%)	13 (7%)	
Positive ICD Screen (QUIP+)			
Any 1 or more disorders	83 (20%)	34 (18%)	0.51
Gambling	4 (1%)	1 (1%)	0.57
Sex	12 (3%)	5 (3%)	0.84
Buying	10 (2%)	4 (2%)	0.80
Eating	35 (8%)	18 (9%)	0.70
Hobbies	29 (7%)	18 (9%)	0.31
Punding	21 (5%)	3 (2%)	0.04
Walking or Driving	3 (1%)	1 (1%)	0.77
STAI - State Score			<0.01
Mean	33.0	27.9	
STAI - Trait Score			<0.01
Mean	32.4	29.1	
UPSIT			<0.01
Mean	22.3	34.0	
Epworth Sleepiness Scale			0.25
Sleepy (≥10)	65 (16%)	23 (12%)	
REM Sleep Disorder Questionnaire			<0.01
Positive (≥5)	159 (38%)	38 (20%)	

Group	UPDRS Part I Psychosis					Fisher's exact p-value (0 vs. any positive response)
	0	1	2	3	4	
PD	402 (96.9%)	13 (3.1%)	0 (0%)	0 (0%)	0 (0%)	0.08
HC	189 (99.5%)	1 (0.5%)	0 (0%)	0 (0%)	0 (0%)	
	UPDRS Part I Apathy					
	0	1	2	3	4	
PD	348 (83.9%)	58 (14.0%)	8 (1.9%)	0 (0%)	1 (0.2%)	<0.001
HC	181 (95.3%)	8 (4.2%)	1 (0.5%)	0 (0%)	0 (0%)	

Psychiatric / Non-Motor Symptoms (Adjusted)			
Variable	Odds Ratio Estimate (PD vs. HC)	Odds Ratio Confidence Limits	p-value*
GDS ≥5	2.309	(1.229, 4.348)	0.009
1 or more QUIP Disorders	1.172	(0.752, 1.828)	0.48
	Parameter Estimates (PD vs. HC)	Standard Error	p-value*
State Trait Anxiety Score			
State Anxiety Subscore	5.127	0.837	<0.001
Trait Anxiety Subscore	3.456	0.765	<0.001

*Adjusted for age (<56, 56-65, and >65) and gender

Conclusion

- Cognitive deficits based on global screening occurs in ≈20% of untreated PD patients.
- Depression, anxiety, apathy, psychosis and RBD symptoms are all more common in untreated PD compared with healthy controls.
- In contrast, ICD symptoms are not more common, supporting the probable association between ICD symptoms and dopaminergic therapy in PD.
- Results from detailed cognitive testing and cognitive categorization are pending.

**PPMI Clinical Sites

United States
University of Rochester – Rochester NY
Oregon Health Sciences University – Portland OR
Baylor College of Medicine – Houston TX
The Parkinson's Institute – Sunnyvale CA
University of Pennsylvania – Philadelphia PA
University of South Florida – Tampa FL
University of California San Diego - San Diego CA
Johns Hopkins University – Baltimore MD
Emory University, School of Medicine – Atlanta GA
Institute for Neurodegenerative Disorders - New Haven CT
Boston University – Boston MA
University of Alabama at Birmingham – Birmingham AL
Northwestern University – Chicago IL
Univ. of Wash & VA Puget Sound Health Care System – Seattle

WA
Cleveland Clinic – Cleveland OH
University of Cincinnati – Cincinnati OH
Banner Research Institute- Phoenix AZ
Parkinson's Disease & Mov. Dis. Center of Boca Raton- Boca Raton FL
Europe
Innsbruck Medical University – Innsbruck Austria
University of Napoli – Napoli Italy
University of Tübingen – Tübingen Germany
Paracelsus-Elena Klinik – Kassel Germany
Imperial College of London – London England
Australia
Macquarie University – Sydney NSW Australia

*PPMI Cognitive-Behavioral Working Group Members and Other Contributors

Roy Alcalay, Paolo Barone, Melanie Braddabur, David Burn, Chelsea Caspell, Cindy Casacelli, William Cho, Thomas Comery, Autilia Cozzolino, Johnna Devoto, Chris Dodds, Jamie Eberling, Alberto Espay, Stewart Factor, Hubert Fernandez, Regan Fong, Douglas Galasko, Sandeep Gupta, David Hewitt, Jim Leverenz, Anita McCoy, Susanne Ostrowitzki, Bernard Ravina, Alistair Reith, Irene Richard, Holly Shill, John Sims, Gretchen Todd, Michelle Ward, Michael York

PPMI Disclosure

PPMI data downloaded from PPMI website at: <http://www.ppmi-info.org/>
PPMI is sponsored and partially funded by The Michael J. Fox Foundation for Parkinson's Research. Other funding partners include a consortium of industry partners.

